InspireMD NSPR 深 沪
已收盘 10-16 16:00:00 美东时间
0.4552
-0.025
-5.25%
华盛通- 最 高0.4849
- 今 开0.4783
- 成交量 9.46万股
- 最 低 0.45
- 昨 收 0.4804
- 总市值 2116.18万
- 52周最高 2.41
- 市盈率 静 --
- 换手率 0.20%
- 52周最低 0.45
- 委 比 -19.05%
- 总股本 4648.91万
- 历史最高 27890625.00
- 量 比 0.61
- 振 幅 7.26%
- 历史最低 0.45
- 每 手 1
- 风险率 0.54%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多InspireMD Amends Warrants to Support CGuard Prime Launch
InspireMD ( ($NSPR) ) has shared an update. On September 21, 2026, InspireMD am...
09-21 21:28
InspireMD Announces Amendments to Certain Series J and Series K Warrants, Providing Potential Gross Proceeds of Up to $11 Million
<p>MIAMI, Sept. 21, 2026 -- InspireMD, Inc. announced amendments to its Series J and Series K warrants to align their exercise with the anticipated FDA approval of CGuard Prime 80 cm in Q4 2026. The amendments modify the exercise price to $0.7674 and adjust the termination date to 5:00 p.m. Eastern time on the earlier of May 15, 2028, or 20 trading days following FDA approval. The changes apply to approximately 4.8 million shares of Series J warr...
09-21 13:00
Full Transcript: InspireMD Q2 2026 Earnings Call
InspireMD (NASDAQ:NSPR) reported second-quarter financial results on Monday. The transcript from the company's second-quarter earnings call has been provided below. This transcript is brought to you by Benzinga APIs. For real-time access to our entire catalog, please visit https://www.benzinga.com/a...
09-17 17:42
InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
InspireMD, Inc. announced inducement grants of 23,764 restricted shares to a new non-executive employee outside its 2021 Equity Incentive Plan, under the 2024 Inducement Plan. The restricted stock will vest in installments through 2029, contingent on continued employment. The grants aim to incentivize the new hire, in compliance with Nasdaq Listing Rule 5635(c)(4).
09-04 20:01
InspireMD to Participate in Upcoming H.C. Wainwright 28th Annual Global Investment Conference
InspireMD公司宣布将于9月14日参加H.C. Wainwright全球投资大会，并计划在会上展示其CGuard® Prime颈动脉支架系统。投资者可通过公司官网观看直播或回放。公司致力于通过MicroNet™技术提升产品在颈动脉支架领域的行业标准。如需更多信息或安排会议，请联系机构代表。
09-03 12:00
InspireMD shares are trading lower after the company reported mixed Q2 financial results.
InspireMD shares are trading lower after the company reported mixed Q2 financial results.
08-18 02:25
InspireMD Q2 EPS $(0.17) Beats $(0.19) Estimate, Sales $1.771M Miss $2.133M Estimate
InspireMD (NASDAQ:NSPR) reported quarterly losses of $(0.17) per share which beat the analyst consensus estimate of $(0.19) by 10.53 percent. This is a 34.62 percent increase over losses of $(0.26) per share from the same period last year. The company reported quarterly sales of $1.771 million which...
08-17 19:01
InspireMD to Announce Second Quarter 2026 Financial Results
InspireMD, Inc. announced it will release its second quarter financial results on August 17, 2026, and host a conference call and webcast at 8:30 a.m. Eastern Time. Interested parties can register via an online form to receive dial-in details. A live audio webcast and recording archive will be available on the company’s Investor Relations page. InspireMD specializes in carotid stent systems using its proprietary MicroNet™ mesh technology.
08-10 20:01
InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
InspireMD's Compensation Committee has approved inducement grants of 221,666 restricted shares to a new non-executive employee, outside the 2021 Equity Incentive Plan, under the 2024 Inducement Plan. The shares will vest over time, with portions vesting in two or three installments between 2027 and 2029, contingent on continued employment. The grants aim to incentivize the employee to join InspireMD, aligning with Nasdaq Listing Rule 5635(c)(4).
08-07 20:01
InspireMD Appoints Carotid Intervention Commercial Leader Kathleen Kennedy as Senior Vice President of Global Sales and Marketing
InspireMD appoints Kathleen Kennedy as Senior Vice President of Global Sales and Marketing. With over 30 years of experience in medical device sales, particularly in carotid intervention, Kennedy previously led U.S. sales for CGuard Prime. Her return strengthens InspireMD's commercial team ahead of the planned U.S. launch of CGuard Prime 80cm for TCAR procedures. CEO Marvin Slosman highlights her expertise and relationships in the field, while Ke...
07-30 20:01
